logo
Popular wellness trend is supposed to help with weight loss — but it may make you eat more

Popular wellness trend is supposed to help with weight loss — but it may make you eat more

Yahoo6 hours ago

Maybe it's better not to take the plunge.
While the ostensible point of most wellness trends is to promote good physical and mental health — as opposed to purely shedding pounds — weight management is often an added perk.
But a fascinating new study published in the journal Physiology & Behavior warns that the caloric dump of one popular practice might be mostly in your head.
Cold plunges and ice baths have made quite the splash in recent years, thanks to their purported boost in mental clarity, blood circulation and metabolism and their reduction in muscle soreness and stress.
And if you've ever spent time in freezing water, you've probably noticed a significant uptick in your appetite — leading you to naturally believe you've really earned that burger.
Sadly, it seems that might not be the case.
Researchers suspect that the 'after-drop' effect — where core body temperature keeps falling after cold exposure, even when you're out of the water — triggers brain regions linked to temperature and energy, boosting appetite.
'Ice baths and cold dips have become really popular, with many people hoping they'll help with weight loss,' David Broom, a professor at UK's Coventry University Research Center for Physical Activity, Sport and Exercise Sciences, said in a statement.
'But our findings show that while cold water does make your body work harder and burn more energy, it also leads to eating more afterward — possibly undoing the potential weight-loss benefits,' he continued.
'Interestingly, people didn't say they felt hungrier during or after the cold water — they just ate more.'
Researchers asked 10 men and five women who were active and healthy to spend 30 minutes in cold water (60 degrees Fahrenheit), hot water (95 degrees) or room temperature water (78 degrees).
Afterwards — in what sounds like the best controlled trial ever — they were asked to eat a plate of pasta until 'comfortably full.'
Of the three groups, the cold water cohort ate a whopping 240 extra calories.
Depending on various factors, spending 30 minutes in a cold plunge — which is, by the way, not really recommended by experts, who advise shooting for no more than 10 minutes due to risk of hypothermia — only burns an estimated 250 to 500 calories, which is why probably why researchers say the overeating might negate the burn.
For what it's worth, these findings align with what experts say about contrast therapy — the art of repeatedly alternating between hot and cold, like shvitzing in a sauna and then jumping into a cold plunge, as one does in modern bathhouses and traditional Finnish culture.
Dr. Hany Demian, CEO of BioSpine and co-founder of Pain Care Clinics, previously told The Post that contrast therapy burns 'a very small amount of calories, but nothing significant.'
He added that the surge in hunger has more to do with 'stomach contraction and relaxation, which stimulates the appetite.'

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

BBC broadcaster John Stapleton issues 'difficult' health update
BBC broadcaster John Stapleton issues 'difficult' health update

Yahoo

timean hour ago

  • Yahoo

BBC broadcaster John Stapleton issues 'difficult' health update

After announcing he had been diagnosed with Parkinson's disease in October 2024. legendary TV presenter John Stapleton has been open about his battle and how his life has changed since. The 79-year-old is renowned for his role on Newsnight, Panorama and GMTV's News Hour. The broadcasting legend shared his devastating diagnosis on BBC One's Morning Live. He said: "Speaking is how I've earned my living for the best part of 50 years 'It's very frustrating sometimes, particularly (when) people are constantly saying to you 'Sorry, what did you say?' And you have to repeat yourself, time and time again. I am fairly pragmatic about the prospect of this getting worse. I try to remain positive, because what's the point of not being?' READ MORE: Strictly Come Dancing's Kevin Clifton says 'it could be the end' in Stacey Dooley relationship update READ MORE: Leanne Campbell says 'we need help' as she shares 'huge news' According the the NHS, Parkinson's disease is a condition in which parts of the brain become progressively damaged over many years, with symptoms including tremors and slow movement. Appearing on Morning Live yesterday, June 25, John shared a health update. He told presenters: "Still got a tremor, which is difficult, makes dressing difficult, a bit of a challenge some mornings. The speech is another problem because you may be able to hear me now loud and clear. I hope you can at least. "But if I go into a room when there's ambient noise like a pub, which I do occasionally frequent as you may know, I sometimes have to repeat myself and it sometimes gets a bit monotonous and a bit frustrating. My limbs are getting stiffer." He added that he is finding the use of the left side of his body difficult and he can't grip things with his left hand. In an emotional admission, he said he is "losing balance" from time-to-time so he has to be careful when walking up and down stairs and getting up too quickly as he might "fall over". Staying positive about his situation he told presenters that aside from the diagnosis, life is a "barrel of laughs". John's mum had Parkinson's so he saw first hand what can happen to people. He described his mum being a "brilliant and outgoing lady" to one who was a "prisoner" in her own home. He continued: "A lot of people live normal lives with Parkinson's, research is going on all the time. So think positive, I am doing the best I can I have a speech therapist who is helping me." BBC Morning Live uploaded a segment of the interview to Instagram. Broadcaster Lucy Meacock commented: "One of the loveliest people you could ever meet. A fine journalist, a brilliant broadcaster & a wonderful person. "I was lucky enough to present with John at the BBC for London Plus many years ago. He was a complete joy to work with always. Huge respect to him for raising awareness of Parkinson's - a great interview." According to the NHS, the symptoms of Parkinson's disease usually develop gradually and are mild at first. The main symptoms of Parkinson's disease affect physical movement: tremor – shaking, which usually begins in the hand or arm and is more likely to occur when the limb is relaxed and resting slowness of movement (bradykinesia) – physical movements are much slower than normal, which can make everyday tasks difficult and result in a distinctive slow, shuffling walk with very small steps muscle stiffness (rigidity) – stiffness and tension in the muscles, which can make it difficult to move around and make facial expressions, and can result in painful muscle cramps (dystonia)

Denis Villeneuve to direct next James Bond film in major franchise shake-up
Denis Villeneuve to direct next James Bond film in major franchise shake-up

Yahoo

time2 hours ago

  • Yahoo

Denis Villeneuve to direct next James Bond film in major franchise shake-up

Denis Villeneuve has been confirmed as the director of the next James Bond film, Amazon MGM Studios has announced. The Oscar-nominated Canadian filmmaker, best known for helming critically acclaimed blockbusters including Dune, Arrival and Blade Runner 2049, will take the reins of the iconic British spy series as part of a significant creative overhaul. The director said in a statement on Wednesday: 'Some of my earliest movie-going memories are connected to 007. 'I grew up watching James Bond films with my father, ever since Dr. No with Sean Connery. I'm a die-hard Bond fan. To me, he's sacred territory. 'I intend to honour the tradition and open the path for many new missions to come. This is a massive responsibility, but also, incredibly exciting for me and a huge honour.' Head of Amazon MGM Studios, Mike Hopkins, said of Villeneuve joining the franchise: 'We are honoured that Denis has agreed to direct James Bond's next chapter. 'He is a cinematic master, whose filmography speaks for itself… James Bond is in the hands of one of today's greatest filmmakers and we cannot wait to get started on 007's next adventure.' Villeneuve's appointment comes as Eon Productions, run by longtime producers Barbara Broccoli and Michael G Wilson, handed over creative control of the franchise in a landmark deal. Wilson and Broccoli had produced the franchise since the death of Albert 'Cubby' Broccoli. The official film franchise had been controlled by members of the Broccoli family, either single-handedly or in partnership with others, since the first 007 movie Dr No in 1962. The move signalled a new era for 007 following the departure of Daniel Craig, who concluded his tenure as Bond with No Time to Die, which grossed $774 million worldwide. A release date has not yet been announced and the casting of the new Bond remains unconfirmed. Speculation continues to swirl, with Aaron Taylor-Johnson, Theo James and James Norton all considered frontrunners for the role. Taylor-Johnson recently stoked fresh speculation when he told press on the red carpet for 28 Years Later that he 'couldn't talk about' his next project. Villeneuve is currently preparing to begin production on Dune: Messiah, the third film in his Dune series, which is set for release in 2026. He is also attached to a number of other high-profile projects, including a Cleopatra biopic, an adaptation of Arthur C. Clarke's Rendezvous with Rama, and a film based on a short story by South Korean science fiction author Kim Bo-young.

Canaccord Genuity Maintains a Buy on Inventiva (IVA) With a $20 Price Target
Canaccord Genuity Maintains a Buy on Inventiva (IVA) With a $20 Price Target

Yahoo

time2 hours ago

  • Yahoo

Canaccord Genuity Maintains a Buy on Inventiva (IVA) With a $20 Price Target

Inventiva S.A. (NASDAQ:IVA) is one of the 13 Best Long-Term Penny Stocks to Buy According to Analysts. Analyst Edward Nash from Canaccord Genuity maintained a Buy rating on Inventiva S.A. (NASDAQ:IVA) on June 5, keeping the price target at $20.00. The rating was based on several factors, including the potential of lanifibranor, the company's lead asset in the MASH space. Lanifibranor's oral administration and direct anti-fibrotic effects distinguish it from other treatments in development, with a primary focus on liver fat reduction. A research scientist in an idiopathic pulmonary fibrosis laboratory, carrying out clinical trials. The analyst also reasoned that Lanifibranor can be used in conjunction with other treatments, including GLP-1s and SGLT2 inhibitors. This factor is a significant boost to its appeal, especially when considering the high prevalence of type 2 diabetes in MASH patients. Nash stated that the drug is progressing well, which can be corroborated by the completion of full enrollment in the Phase III NATiV3 trial and the anticipated top-line data in H2 2026. Major pharmaceutical companies are also showing increasing interest in the MASH space, further supporting the optimistic outlook for Inventiva S.A. (NASDAQ:IVA). Inventiva S.A. (NASDAQ:IVA) is a clinical-stage biopharmaceutical company that develops oral small-molecule therapies to treat non-alcoholic steatohepatitis or NASH. It also develops therapies for other diseases with considerable unmet medical needs. While we acknowledge the potential of IVA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store